Search

September 510K Clearance Highlights

Accel Groups select ten medical devices or in vitro diagnostic reagents from the monthly 510(k) clearance list (five from Chinese manufacturers and five from foreign manufacturers) for brief introductions.
Roche's TAGS technology enables simultaneous detection of 12 respiratory viruses, including influenza A, influenza B, respiratory syncytial virus (RSV), and COVID-19.
On September 4, the FDA released a draft guidance that significantly revises its previous guidance on the use of voluntary patient preference information (PPI) in medical devices, shifting the focus from the premarket stage to the entire product lifecycle.
Accel Groups select ten medical devices or in vitro diagnostic reagents from the monthly 510(k) clearance list (five from Chinese manufacturers and five from foreign manufacturers) for brief introductions. This aims to provide the latest global updates on medium and low-risk devices or reagents.
FDA issued a draft guidance on August 22 detailing the types of modifications it considers suitable for inclusion in a Predetermined Change Control Plan (PCCP) and the information sponsors should include in their premarket approval (PMA), de novo, or 510(k) submissions to support their proposed PCCP.
FDA published the draft guidance "Dental Curing Lights - Premarket Notification (510(k)) Submissions - Draft Guidance for Industry and Food and Drug Administration Staff," on July 12, 2024, for feedback. Feedback needs to be submitted by September 10, 2024.
In October 2022, the FDA launched the "Total Product Life Cycle Advisory Program (TAP)" pilot to accelerate the development of innovative medical devices and technologies critical to public health. TAP facilitates "early, frequent, and strategic communication" with the FDA to enhance collaboration with manufacturers and third parties, speeding up patient access to innovative medical devices.
The European Society of Cardiology and the European Association of Percutaneous Cardiovascular Interventions issued a consensus statement in March 2023 stating that renal sympathetic denervation can be used as adjunctive therapy for patients with uncontrolled hypertension who have had inadequate responses to medications and lifestyle changes.
In 2013, Stryker acquired Mako Surgical and has since maintained a leading position in the robotics field. In 2019, Zimmer Biomet's Rosa knee system received 510(k) clearance, entering the market. J&J took longer to enter the market, with its Velys product first receiving FDA clearance in 2021. Recently, the company has expanded the system's scope of use.
Truist analyst Richard Newitter indicates that feedback from the Heart Rhythm Society (HRS) meeting suggests 50% to 70% of doctors will "immediately" adopt the technology.

Market News

Product News

Coming soon